LJPC La Jolla Pharmaceutical Company

30.01
-0.41  -1%
Previous Close 30.42
Open 30.49
Price To book 4.32
Market Cap 663.91M
Shares 22,123,000
Volume 216,811
Short Ratio 10.34
Av. Daily Volume 587,095

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial to be initiated in mid-2017.
LJPC-401
Beta thalassemia patients suffering from iron overload
Phase 3 data released February 27, 2016 - primary endpoint hit. Secondary endpoints not mentioned. Data published May 21, 2017 confirmed primary endpoint was met but with lack of mortality improvement.
LJPC-501
Catecholamine-resistant hypotension (CRH)

Latest News

  1. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : June 22, 2017
  2. ETFs with exposure to La Jolla Pharmaceutical Co. : June 15, 2017
  3. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : June 8, 2017
  4. Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential
  5. Results of ATHOS-3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine
  6. Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options
  7. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : May 19, 2017
  8. Here's Why La Jolla Pharmaceuticals Company Is Soaring
  9. La Jolla Pharmaceutical posts 1Q loss
  10. La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress
  11. La Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : April 24, 2017
  12. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : April 21, 2017
  13. La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
  14. La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering of Common Stock
  15. Biotechs Remain the Best Place For Stock Picking
  16. La Jolla Pharmaceutical (LJPC) is in Overbought Territory: What's Next?
  17. La Jolla Pharmaceutical Co. :LJPC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  18. Biotech Bounce Set to Pick Up Steam
  19. 6 Stocks on the Move With Unusual Volume
  20. Dow Continues Record Streak: Today's Research Reports on La Jolla Pharmaceutical and Advanced Micro Devices

SEC Filings

  1. 8-K - Current report 17859728
  2. 8-K - Current report 17854149
  3. 8-K - Current report 17800682
  4. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 17796452
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17788996
  6. 8-K - Current report 17756646
  7. 8-K - Current report 17710877
  8. 424B5 - Prospectus [Rule 424(b)(5)] 17710872
  9. 424B2 - Prospectus [Rule 424(b)(2)] 17701531
  10. 8-K - Current report 17701509